This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

AVEO Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Michael Bailey

Algemeen directeur

US$2.9m

Totale compensatie

Percentage CEO-salaris	20.0%
Dienstverband CEO	8yrs
Eigendom CEO	1.0%
Management gemiddelde ambtstermijn	2.7yrs
Gemiddelde ambtstermijn bestuur	8yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Michael Bailey's beloning veranderd ten opzichte van AVEO Pharmaceuticals's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2022	n/a	n/a	-US$29m
Jun 30 2022	n/a	n/a	-US$36m
Mar 31 2022	n/a	n/a	-US$41m
Dec 31 2021	US$3m	US$590k	-US$53m
Sep 30 2021	n/a	n/a	-US$58m
Jun 30 2021	n/a	n/a	-US$56m
Mar 31 2021	n/a	n/a	-US$49m
Dec 31 2020	US$2m	US$565k	-US$36m
Sep 30 2020	n/a	n/a	-US$29m
Jun 30 2020	n/a	n/a	-US$4m
Mar 31 2020	n/a	n/a	US$452k
Dec 31 2019	US$2m	US$528k	US$9m
Sep 30 2019	n/a	n/a	US$36m
Jun 30 2019	n/a	n/a	-US$3m
Mar 31 2019	n/a	n/a	US$4m
Dec 31 2018	US$3m	US$528k	-US$5m
Sep 30 2018	n/a	n/a	-US$24m
Jun 30 2018	n/a	n/a	-US$28m
Mar 31 2018	n/a	n/a	-US$65m
Dec 31 2017	US$1m	US$480k	-US$65m
Sep 30 2017	n/a	n/a	-US$74m
Jun 30 2017	n/a	n/a	-US$53m
Mar 31 2017	n/a	n/a	-US$28m
Dec 31 2016	US$1m	US$444k	-US$27m

Compensatie versus markt: De totale vergoeding ($USD 2.94M ) Michael } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 1.18M ).

Compensatie versus inkomsten: De vergoeding van Michael is gestegen terwijl het bedrijf verliesgevend is.

CEO

Michael Bailey (57 yo)

8yrs

Tenure

US$2,943,905

Compensatie

Mr. Michael P. Bailey serves as an Independent Chairman at IMV Inc. since May 01, 2022 and has been its Independent Director since July 20, 2020. He has been Chief Executive Officer and President of AVEO P...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Michael Bailey	CEO, President & Director	8yrs	US$2.94m	0.98% € 4.7m
Erick Lucera	Chief Financial Officer	3yrs	US$1.24m	0% € 0
Michael Ferraresso	Chief Commercial Officer	no data	US$1.25m	0.038% € 184.2k
Jeb Ledell	Chief Operating Officer	1.1yrs	geen gegevens	0% € 0
Danielle Holland	VP of Legal & Corporate Secretary	2yrs	geen gegevens	geen gegevens
Kevin Peacock	Senior Vice President of Marketing	3.2yrs	geen gegevens	geen gegevens
David Crist	Vice President of Sales	2.3yrs	geen gegevens	geen gegevens
Catherine DeRose	Vice President of Human Resources	2.3yrs	geen gegevens	geen gegevens
Lisa Bruneau	VP of Finance & Treasurer	7yrs	geen gegevens	geen gegevens

2.7yrs

Gemiddelde duur

54.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van VPA1 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.7 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Michael Bailey	CEO, President & Director	8yrs	US$2.94m	0.98% € 4.7m
Anthony Evnin	Independent Director	20.8yrs	US$127.61k	0.12% € 578.0k
Kenneth Bate	Independent Chairman	15.1yrs	US$158.73k	0.0011% € 5.2k
Raju Kucherlapati	Member of Scientific Advisory Board	no data	US$3.00k	geen gegevens
Charles Sawyers	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
H. Horvitz	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Tyler Jacks	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Lynda Chin	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Lewis Cantley	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Gregory Mayes	Independent Director	3.9yrs	US$120.61k	0% € 0
Douglas Hanahan	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Scarlett Spring	Independent Director	3.2yrs	US$126.84k	0% € 0

8.0yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van VPA1 wordt beschouwd als ervaren (gemiddelde ambtstermijn 8 jaar).

This company listing is no longer active

AVEO Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

AVEO Oncology Appoints Martin Birkhofer as Its Chief Medical Officer

Insufficient new directors

AVEO Oncology Announces Appointment of Mike Ferraresso to Chief Commercial Officer

AVEO Pharmaceuticals, Inc. Appoints Corinne Epperly as Member of the Board and to Its Nominating and Governance Committee and Compensation Committee

AVEO Pharmaceuticals, Inc. Announces the Departure of Karuna Rubin, Senior Vice President and General Counsel

AVEO Pharmaceuticals, Inc. Announces Management Changes

Recent updates

LG Chem, Ltd. (KOSE:A051910) completed the acquisition of AVEO Pharmaceuticals, Inc. (NasdaqCM:AVEO) from a group of shareholders.

AVEO Oncology Appoints Martin Birkhofer as Its Chief Medical Officer

Insufficient new directors

Third quarter 2022 earnings released: US$0.094 loss per share (vs US$0.30 loss in 3Q 2021)

Aveo Pharmaceuticals, Inc. Withdraws Earnings Guidance for the Year 2022

AVEO Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 07, 2022

AVEO Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Full Year 2022

Second quarter 2022 earnings released: US$0.24 loss per share (vs US$0.40 loss in 2Q 2021)

AVEO Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 04, 2022

AVEO Pharmaceuticals, Inc.(NasdaqCM:AVEO) dropped from Russell Microcap Value Index

AVEO Oncology Announces Updated National Comprehensive Cancer Network Clinical Practice Guidelines Elevate Fotivda (Tivozanib) to Category 1 Treatment for Relapsed or Refractory Advanced Renal Cell Carcinoma Patients

First quarter 2022 earnings released: US$0.30 loss per share (vs US$0.81 loss in 1Q 2021)

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

AVEO Pharmaceuticals, Inc. Announces Positive New Long-Term PFS Data from Phase 3 TIVO-3 Study of FOTIVDA® in Third- and Fourth-Line Renal Cell Carcinoma

Aveo Oncology Presents Three Posters for Tivozanib/Immunotherapy Combinations at the 2022 ASCO GI Cancers Symposium

Aveo Oncology Highlights Recent Progress and 2022 Outlook

Third quarter 2021 earnings released: US$0.30 loss per share (vs US$0.33 loss in 3Q 2020)

AVEO Oncology Announces Ficlatuzumab Grants Fast Track Designation by the U.S. FDA

AVEO Pharmaceuticals, Inc.(NasdaqCM:AVEO) dropped from Russell 3000E Value Index

AVEO Oncology Announces Positive Results from Randomized Phase 2 Study of Ficlatuzumab in Combination with Cetuximab in Pan-Refractory, Metastatic HNSCC

CANbridge Life Sciences Ltd. and AVEO Pharmaceuticals, Inc. Terminate Collaboration and License Agreement

AVEO Oncology Announces Collaboration with Bristol Myers Squibb to Evaluate Fotivda® in Combination with Opdivo® in Pivotal Phase 3 Tinivo-2 Trial in Io Relapsed Renal Cell Carcinoma

AVEO Oncology Announces U.S. FDA Approval of FOTIVDA (tivozanib) for the Treatment of Adult Patients with Relapsed or Refractory Advanced Renal Cell Carcinoma

AVEO Oncology Announces Appointment of Mike Ferraresso to Chief Commercial Officer

AVEO Pharmaceuticals, Inc. Appoints Corinne Epperly as Member of the Board and to Its Nominating and Governance Committee and Compensation Committee

AVEO Pharmaceuticals, Inc. Announces the Departure of Karuna Rubin, Senior Vice President and General Counsel

AVEO Oncology Announces Results from Phase 1b Portion of DEDUCTIVE Study of Tivozanib (FOTIVDA®) in Combination with IMFINZI® (Durvalumab) in Previously Untreated Metastatic Hepatocellular Carcinoma

AVEO Pharmaceuticals, Inc. Announces Management Changes

AVEO Oncology and EUSA Pharma Announce Annals of Oncology Publication of Data from Phase 1b/2 TiNivo Study in Renal Cell Carcinoma

AVEO Pharmaceuticals, Inc. announced that it has received $7.499997 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

AVEO Pharmaceuticals, Inc.(NasdaqCM:AVEO) dropped from S&P Global BMI Index

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd